LONDON (Reuters) - Lower-cost copies of complex biotech drugs, known as biosimilars, could save the United States and Europe's five top markets as much as 98 billion euros ($110 bln) by 2020, a new analysis showed on Tuesday.
http://ift.tt/xePdMM
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire